RADY CHILDRENS HOSPITAL - SAN DIEGO
- Type
- Teaching hospital
- Where
- SAN DIEGO, CA
- Medicare CCN
- 053303
- Received
- $622,090 in 244 records, 2019 ($135,425 general, $486,664 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
- Nonprofit: RADY CHILDRENS HOSPITAL SAN DIEGO Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 71 | $135,425 |
| 2019 | Research payment | 173 | $486,664 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 173 | $486,664 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $40,476 |
| Education | 3 | $33,500 |
| Space rental or facility fees (teaching hospital only) | 13 | $32,124 |
| Gift | 44 | $14,829 |
| Grant | 6 | $13,815 |
| Food and Beverage | 3 | $528 |
| Charitable Contribution | 1 | $150 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Linvatec Corporation | $1,014 | Grant | In-kind items and services | MICROFREE Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-18 | Merck Sharp & Dohme LLC | $8,507 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-12-14 | 180 Medical, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-12 | PFIZER INC. | $3,772 | Research payment | In-kind items and services | LIPITOR Drug, CARDIOVASCULAR;METABOLIC DISEASE | LIPITOR IN INFANTS AND CHILDREN WITH CORONARY ARTERY ABNORMALITIES IN ACUTE KAWASAKI DISEASE | 2019 |
| 2019-12-11 | Merck Sharp & Dohme LLC | $10,000 | Research payment | Cash or cash equivalent | NOXAFIL Drug, INFECTIOUS DISEASE | A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in P | 2019 |
| 2019-12-09 | KARL STORZ Endoscopy-America | $417 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-12-09 | Merck Sharp & Dohme LLC | $70 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $16 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-12-06 | KARL STORZ Endoscopy-America | $1,258 | Gift | In-kind items and services | TELESCOPE, HOPKINS, STRAIGHT Device, ENT | 2019 | |
| 2019-12-06 | KARL STORZ Endoscopy-America | $426 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-12-06 | KARL STORZ Endoscopy-America | $286 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-12-06 | KARL STORZ Endoscopy-America | $79 | Gift | In-kind items and services | ADAPTOR,LOCKING.F/27015, Device, ENT | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,583 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-11-26 | KARL STORZ Endoscopy-America | $186 | Gift | In-kind items and services | TUBE,BRONCH,'DOESEL-HUZLY' Device, ENT | 2019 | |
| 2019-11-22 | KARL STORZ Endoscopy-America | $144 | Gift | In-kind items and services | TUBE,UNIVERSAL BRONCH.W/O Device, ENT | 2019 | |
| 2019-11-19 | Merck Sharp & Dohme LLC | $39 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-11-12 | Merck Sharp & Dohme LLC | $391 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-11-12 | KARL STORZ Endoscopy-America | $228 | Gift | In-kind items and services | HOPKINS 30 TELESCOPE, AUTOCLAVABLE Device, ODONTOLOGY | 2019 | |
| 2019-11-12 | Merck Sharp & Dohme LLC | $134 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-11-08 | Merck Sharp & Dohme LLC | $1,520 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-11-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-11-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $1,258 | Gift | In-kind items and services | TELESCOPE, HOPKINS, STRAIGHT Device, ENT | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $185 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $117 | Gift | In-kind items and services | CARRIER,FIBER OPTIC LIGHT. Device, ENT | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $79 | Gift | In-kind items and services | ADAPTOR,LOCKING.F/27015, Device, ENT | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TUBE,INSERTABLE SUCTION,F/ Device, ENT | 2019 | |
| 2019-11-07 | KARL STORZ Endoscopy-America | $29 | Gift | In-kind items and services | CANNULA,INJECTION. F/POSITIVE Device, ENT | 2019 | |
| 2019-11-06 | KARL STORZ Endoscopy-America | $196 | Gift | In-kind items and services | HOPKINS II Telescope 0, 2.7 mm, 18 cm Device, ENT | 2019 | |
| 2019-11-05 | Incyte Corporation | $6,346 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-11-05 | KARL STORZ Endoscopy-America | $210 | Gift | In-kind items and services | CLIP,STEINER-BENJAMIN-HAVAS, Device, ENT | 2019 | |
| 2019-11-05 | KARL STORZ Endoscopy-America | $196 | Gift | In-kind items and services | TELESCOPE, HOPKINS II LATERAL, 70', Device, ENT | 2019 | |
| 2019-11-05 | KARL STORZ Endoscopy-America | $196 | Gift | In-kind items and services | TELESCOPE, HOPKINS,30'AUTOCLAV Device, GYNECOLOGY | 2019 | |
| 2019-11-05 | KARL STORZ Endoscopy-America | $121 | Gift | In-kind items and services | CONTAINER, 2 RIGID SCOPES, 4MM X 18CM Device, CLEANING, STERILIZATION, CARE | 2019 | |
| 2019-11-05 | KARL STORZ Endoscopy-America | $121 | Gift | In-kind items and services | CONTAINER, 2 RIGID SCOPES, 4MM X 18CM Device, CLEANING, STERILIZATION, CARE | 2019 | |
| 2019-11-04 | Merck Sharp & Dohme LLC | $15,170 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-11-04 | KARL STORZ Endoscopy-America | $571 | Gift | In-kind items and services | TUBE,BRONCH,'DOESEL-HUZLY' Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $381 | Gift | In-kind items and services | TUBE,BRONCH,'DOESEL-HUZLY' Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $225 | Gift | In-kind items and services | TELESCOPE, HOPKINS, STRAIGHT Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $225 | Gift | In-kind items and services | TELESCOPE, HOPKINS, STRAIGHT Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $190 | Gift | In-kind items and services | TUBE,BRONCH,'DOESEL-HUZLY' Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $111 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-11-04 | KARL STORZ Endoscopy-America | $21 | Gift | In-kind items and services | TONSIL AND ADENOID SET Device, ENT | 2019 | |
| 2019-11-01 | KARL STORZ Endoscopy-America | $573 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-11-01 | KARL STORZ Endoscopy-America | $102 | Gift | In-kind items and services | TONSIL AND ADENOID SET Device, ENT | 2019 | |
| 2019-10-30 | Merck Sharp & Dohme LLC | $3,250 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-29 | KARL STORZ Endoscopy-America | $516 | Gift | In-kind items and services | FORCEPS,CIRCULAR CUP BIOPSY. Device, ENT | 2019 | |
| 2019-10-29 | KARL STORZ Endoscopy-America | $196 | Gift | In-kind items and services | HOPKINS II TELESCOPE 30, 2.7MM, 18CM Device, ENT | 2019 | |
| 2019-10-28 | Merck Sharp & Dohme LLC | $100 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-10-28 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-10-25 | Merck Sharp & Dohme LLC | $9,159 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-25 | KARL STORZ Endoscopy-America | $395 | Gift | In-kind items and services | OPTICAL FORCEPS Device, ENT | 2019 | |
| 2019-10-24 | KARL STORZ Endoscopy-America | $4,131 | Gift | In-kind items and services | FORCEPS,CIRCULAR CUP BIOPSY. Device, ENT | 2019 | |
| 2019-10-24 | KARL STORZ Endoscopy-America | $517 | Gift | In-kind items and services | ADAPTOR,LOCKING.F/27015, Device, ENT | 2019 | |
| 2019-10-24 | KARL STORZ Endoscopy-America | $50 | Gift | In-kind items and services | TUBE,RIGID SUCTION.W/THUMB Device, ENT | 2019 | |
| 2019-10-24 | KARL STORZ Endoscopy-America | $13 | Gift | In-kind items and services | FORCEPS, CRILE HAEMOSTATIC, Device, ENT | 2019 | |
| 2019-10-23 | KARL STORZ Endoscopy-America | $169 | Gift | In-kind items and services | TUBE,WHISTLE TIP SUCTION. Device, ENT | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $258 | Gift | In-kind items and services | FORCEPS,CIRCULAR CUP BIOPSY. Device, ENT | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $190 | Gift | In-kind items and services | ADAPTOR,LOCKING.F/27015, Device, ENT | 2019 | |
| 2019-10-22 | Merge Healthcare Incorporated | $171 | Food and Beverage (5 payments) | Cash or cash equivalent | Device, Medical Imaging | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $74 | Gift | In-kind items and services | TONSIL AND ADENOID SET Device, ENT | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $64 | Gift | In-kind items and services | TONSIL AND ADENOID SET Device, ENT | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $33 | Gift | In-kind items and services | CARRIER, FIBER OPTIC LIGHT, Device, ENT | 2019 | |
| 2019-10-22 | KARL STORZ Endoscopy-America | $13 | Gift | In-kind items and services | FORCEPS, CRILE HAEMOSTATIC, Device, ENT | 2019 | |
| 2019-10-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-10-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-10-08 | PFIZER INC. | $2,152 | Research payment | In-kind items and services | ZAVICEFTA NEONATAL SEPSIS TRIAL | 2019 | |
| 2019-10-08 | Merck Sharp & Dohme LLC | $48 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $39 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-27 | Merck Sharp & Dohme LLC | $284 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-09-26 | Merck Sharp & Dohme LLC | $64 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-09-25 | Merck Sharp & Dohme LLC | $23,860 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-09-18 | MED-EL Corporation | $1,000 | Grant | Cash or cash equivalent | MED-EL Maestro Cochlear Implant System Device, Cochlear Implant | 2019 | |
| 2019-09-16 | Merck Sharp & Dohme LLC | $10,500 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-09-13 | Merck Sharp & Dohme LLC | $453 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-09-12 | Merck Sharp & Dohme LLC | $494 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-11 | Merck Sharp & Dohme LLC | $1,154 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and | 2019 |
| 2019-09-10 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-09-10 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $39 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-10 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-09 | Merck Sharp & Dohme LLC | $2,385 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-09-09 | Merck Sharp & Dohme LLC | $1,136 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-09-05 | Daiichi Sankyo Inc. | $1,062 | Research payment | Cash or cash equivalent | WEL-A-U307 | 2019 | |
| 2019-08-21 | Merck Sharp & Dohme LLC | $2,060 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-08-21 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-08-19 | Merck Sharp & Dohme LLC | $2,060 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-08-14 | Merck Sharp & Dohme LLC | $2,112 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-08-13 | Cochlear Americas | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nucleus Device, Implantable hearing solution | 2019 | |
| 2019-08-09 | Merck Sharp & Dohme LLC | $4,900 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $118 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-08-01 | Zimmer Biomet Holdings, Inc. | $1,257 | Grant | Cash or cash equivalent | Grants Device, General | 2019 | |
| 2019-07-30 | Advanced Bionics, LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HiResolution Bionic Ear System Device, OTOLARYNGOLOGY | 2019 | |
| 2019-07-26 | Merck Sharp & Dohme LLC | $760 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-07-26 | Merck Sharp & Dohme LLC | $760 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-07-25 | Merck Sharp & Dohme LLC | $90 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-07-25 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-07-15 | Merck Sharp & Dohme LLC | $2,840 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-07-11 | Daiichi Sankyo Inc. | $283 | Research payment | Cash or cash equivalent | WEL-A-U307 | 2019 | |
| 2019-07-10 | Incyte Corporation | $76 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-10 | Incyte Corporation | $76 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-10 | Incyte Corporation | $76 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-10 | Incyte Corporation | $76 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-10 | Incyte Corporation | $58 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-10 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-07-03 | Catalent Pharma Solutions, LLC | $150 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-07-01 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Pulmozyme Biological, Virology & Specialty Care | 2019 | |
| 2019-06-25 | Merck Sharp & Dohme LLC | $78 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-06-21 | Merck Sharp & Dohme LLC | $723 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-06-19 | Merck Sharp & Dohme LLC | $963 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $1,804 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $1,520 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $760 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $284 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-06-13 | Daiichi Sankyo Inc. | $3,969 | Research payment | Cash or cash equivalent | WEL-A-U307 | 2019 | |
| 2019-06-13 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Creon Drug, Endocrinology | 2019 | |
| 2019-06-12 | Merck Sharp & Dohme LLC | $3,150 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-Day Comparator in Subjects 12 to 18 Years with c | 2019 |
| 2019-06-12 | Merck Sharp & Dohme LLC | $1,260 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-Day Comparator in Subjects 12 to 18 Years with c | 2019 |
| 2019-06-12 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-Day Comparator in Subjects 12 to 18 Years with c | 2019 |
| 2019-06-12 | Merck Sharp & Dohme LLC | $630 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-Day Comparator in Subjects 12 to 18 Years with c | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $2,840 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-06-07 | Merck Sharp & Dohme LLC | $4,316 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-06-06 | Daiichi Sankyo Inc. | $2,551 | Research payment | Cash or cash equivalent | WEL-A-U307 | 2019 | |
| 2019-06-05 | Gilead Sciences, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-06-04 | Becton, Dickinson and Company | $40,476 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-24 | PFIZER INC. | $7,200 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | THE UNITED STATES PEDIATRIC MULTICENTER PNEUMOCOCCAL SURVEILLANCE | 2019 |
| 2019-05-24 | PFIZER INC. | $4,400 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | THE UNITED STATES PEDIATRIC MULTICENTER PNEUMOCOCCAL SURVEILLANCE | 2019 |
| 2019-05-14 | Electromed, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2019 | |
| 2019-05-09 | Merck Sharp & Dohme LLC | $167 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $277 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $49 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-05-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-05-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-05-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $18 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-05-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-05-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-04-26 | GenMark Diagnostics, Inc. | $142 | Food and Beverage (2 payments) | In-kind items and services | 2019 | ||
| 2019-04-16 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-04-15 | Merck Sharp & Dohme LLC | $760 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Ef | 2019 |
| 2019-04-15 | Merck Sharp & Dohme LLC | $710 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-04-11 | Daiichi Sankyo Inc. | $2,290 | Research payment | Cash or cash equivalent | Welchol Drug, Metabolism | WEL-A-U307 | 2019 |
| 2019-04-10 | Merck Sharp & Dohme LLC | $5,090 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-04-10 | Regeneron Healthcare Solutions, Inc. | $5,000 | Grant | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2019 | |
| 2019-04-09 | OrthoPediatrics Corp. | $10,000 | Education | Cash or cash equivalent | Orthopediatric Implants Device, Orthopediatric Implants | 2019 | |
| 2019-04-08 | Eli Lilly and Company | $884 | Research payment | In-kind items and services | TRULICITY Drug, Diabetes | A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACE | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $758 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $494 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $391 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-04-08 | Incyte Corporation | $71 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $7 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $6 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | 2019 | |
| 2019-04-05 | Eli Lilly and Company | $3,534 | Research payment | In-kind items and services | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREAT | 2019 | |
| 2019-04-05 | Merck Sharp & Dohme LLC | $2,820 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-04-04 | MED-EL Corporation | $750 | Grant | Cash or cash equivalent | MED-EL Maestro Cochlear Implant System Device, Cochlear Implant | 2019 | |
| 2019-03-28 | Medtronic USA, Inc. | $3,402 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MazorX - Renaissance Device, Enabling | 2019 | |
| 2019-03-27 | Merck Sharp & Dohme LLC | $10,000 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-03-23 | Merck Sharp & Dohme LLC | $1,020 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
| 2019-03-21 | Merck Sharp & Dohme LLC | $3,788 | Research payment | Cash or cash equivalent | SIVEXTRO Drug, INFECTIOUS DISEASE | Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-Day Comparator in Subjects 12 to 18 Years with c | 2019 |
| 2019-03-21 | Merck Sharp & Dohme LLC | $167 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase III Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 Tedizoli | 2019 |
| 2019-03-15 | Daiichi Sankyo Inc. | $3,453 | Research payment | Cash or cash equivalent | Welchol Drug, Metabolism | WEL-A-U307 | 2019 |
| 2019-03-15 | Merck Sharp & Dohme LLC | $2,385 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Eff | 2019 |
The latest 200 records of 244.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Diego, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Diego, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 1,389,526 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 1,386,932 | 3,298,634 | 39,538,223 |
| Median age B01002 | 36.2 | 37.3 | 37.9 |
| Under 18 B01001 | 18.4% | 20.9% | 22.0% |
| 65 and over B01001 | 14.6% | 15.4% | 15.7% |
| Households B11001 | 530,412 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 25.1% | 22.8% | 27.0% |
| Median household income B19013 | $108,077 | $106,268 | $99,122 |
| Median family income B19113 | $128,006 | $122,377 | $113,346 |
| Per capita income B19301 | $57,083 | $51,976 | $49,513 |
| Poverty rate B17001 | 11.0% | 10.3% | 12.0% |
| Unemployment rate B23025 | 6.0% | 6.1% | 6.6% |
| Civilian labor force B23025 | 755,893 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 23.5 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 51.0% | 43.2% | 37.1% |
| Housing units B25001 | 568,668 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 47.3% | 54.6% | 55.9% |
| Renters B25003 | 52.7% | 45.4% | 44.1% |
| Median home value B25077 | $906,700 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,313 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 40.9% | 42.4% | 33.8% |
| Black B03002 | 5.3% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 29.8% | 34.6% | 40.2% |
| Asian B03002 | 17.3% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Diego, CA.
Comments